Saturday, December, 15, 2018 12:23:38

American pharmaceutical conglomerate, Merck & Co. has recently inaugurated a state-of-the-art M Lab™ Collaboration Center in São Paulo, Brazil, so as to serve customers in the Latin America region.

Sources suggests that the center will effectively provide life science customers with a shared, exploratory environment, that would allow individuals to closely collaborate with Merck engineers and scientists to unravel their toughest challenges and further advance the production and development of new therapies.

According to an official press release, Udit Batra, CEO, Life Science, Merck, said that the biopharmaceutical industry in Brazil and Latin America is rapidly growing, amid increasing demand for new, cost-effective therapies around the world.

With M Lab™ Collaboration Center, customers will benefit from Merck’s profound technical expertise to develop processes for manufacturing drugs safer, faster, more effectively, said Batra.

As per sources, the 1,000-sqm lab facility would include bench scale labs and non-GMP trails for customers to engage in process development support, demonstration, troubleshooting and hands-on training.

Incidentally, the M Lab™ Collaboration Center would be one of nine centers around the world, which allows pharmaceutical manufacturers to explore new ways to improve processes, increase productivity, and reduce risks.

For the record, in 1995, Merck opened its first customer involving laboratory in Massachusetts, USA. The global pharma network has since then grown steadily over the years, by meeting the training and process development needs of customers in local regions as well as allowing and ensuring successful technology transfer between countries for global customers.

Reportedly, each year, more than 1,500 people visit Merck’s M Lab Collaboration centers, where they work in collaboration with Merck’s team of experts and get access to sizing and simulation methods and tools as well as take benefit of analytical and modeling support.

Sources familiar with the matter claim that formal bioprocessing courses would also be available, along with traditional classroom-style training and interactive, hands-on sessions in the new center. Apparently, Merck operates similar centers in countries such as China, Japan, Singapore, South Korea, France, India and the United States.